To evaluate the role and the prognostic value of bronchoalveolar lavage (BAL) in scleroderma patients with interstitial lung disease. We reviewed the records of 79 patients with systemic sclerosis (SSc) who had dyspnea and pulmonary involvement and underwent BAL study. Sixty-two patients were prospectively followed up for 12-36 months and re-evaluated by pulmonary function tests (PFTs). Seventy-nine SSc patients were enrolled (71 F and 8 M), 55 with limited and 24 with a diVuse form; mean age 55 § 13 years; mean disease duration 55.2 § 59 months. All patients were ANA positive, of these 30 were anti-topoisomerase-1 positive (anti-Topo1) and 22 were anti-centromere positive (ACA). Thirty-one patients had alveolitis (39.2%) that was neutrophilic in 12 patients, eosinophilic in 3 and mixed (neutrophilic and eosinophilic) in 16 patients. Compared to patients without alveolitis, those with alveolitis had a signiWcant reduction of carbon monoxide diVusing capacity (DLCO), forced vital capacity (FVC) and more elevated lung high-resolution computed tomography (HRCT) scores. Furthermore, alveolar clearance was signiWcantly accelerated. No diVerences were found between patients with and without alveolitis regarding disease subsets (diVuse vs limited-SSc); a signiWcant predominance of anti-Topo1 antibodies was found in the alveolitis group and of ACA antibodies in the non-alveolitis cohort. During the follow-up, (range: 12-36 months) 62 patients, 26 with and 36 without alveolitis were re-evaluated with PFTs. In the alveolitis group, 12 patients (46.1%) showed stable lung function parameters and 14 had worsened (53.8%). In this group, 20 patients (77%) received cyclophosphamide (CYC): 11 (55%) worsened (5 of them died of cardio-pulmonary complications) and 9 (45%) remained stable. Six patients could not be treated; of these 3 remained stable and 3 worsened. Among 36 patients with normal BAL, 11 (30.5%) showed stable lung function parameters, 13 improved (36.1%) and 12 worsened (33.3%); in this last group, 2 patients died of extra-pulmonary complications. Six patients, with progression of lung Wbrosis, were treated with CYC: 3 of them improved and 3 remained stable. Our study revealed a trend toward a more severe course in the SSc patients with BAL alveolitis; probably the non-signiWcant result is related to the low number of the examined subjects and to the selection criteria. However, BAL remains the only tool to exclude lung infections and, in our experience, a useful instrument to evaluate interstitial lung disease in SSc patients.
Introduction
Lung involvement represents the most relevant complication and the main cause of morbidity and mortality in systemic sclerosis (SSc) . During the course of the disease, about 80% of patients with SSc develop alveolar inXammation and pulmonary Wbrosis [1] . Other than pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) of the lung, bronchoalveolar lavage (BAL) showed a prognostic value in predicting increased mortality, identifying alveolitis before extensive lung involvement has developed and allowing an earlier intervention [2] . Furthermore, BAL cultures and histological lung examination can help to identify patients with infection or other lung complications [3] . However, the pathogenetic role of alveolitis detected by BAL in SSc is uncertain because it is not known whether the cells recovered are the cause or a consequence of the lung Wbrosis [4] .
This study summarizes our experience in deWning the diagnostic and prognostic value of BAL alveolitis in a series of SSc patients.
Patients and methods
In this retrospective study, records of all scleroderma patients with pulmonary interstitial involvement who underwent BAL study were analyzed. All patients fulWlled the criteria proposed by the American College of Rheumatology [5] and were grouped according to LeRoy et al. in patients with limited and diVuse skin involvement [6] . ModiWed Rodnan skin score was performed for all patients [7] .
The baseline clinical characteristics of the patients, including demographic data, autoantibody status and disease duration (evaluated from the Wrst symptom, except Raynaud's phenomenon), were retrieved from the database. Antinuclear antibodies (ANA) were determined by indirect immunoXuorescence using Hep-2 cells as substrates and autoantibody speciWcities were further assessed by enzymelinked immunosorbent assay (ELISA; [8] ).
Inclusion criteria were as follows: (a) presence of dyspnea on exertion¸grade 2 according to the Mahler Baseline Dyspnea index [9] ; (b) carrying out at baseline pulmonary function testing (PFTs), chest HRCT, 99m Technetium-DTPA Lung Scintigraphy with abnormality at least of one of these exams. Current smokers, patients with positive BAL cultures for ongoing infection and patients with pulmonary hypertension (deWned as a value of systolic echocardiographic pulmonary pressure >35 mmHg) were excluded.
At baseline, all patients were on treatment with Ca-antagonist associated in 35 cases with low dosages of penicillamine (150 or 300 mg die) and glucocorticoids (methylprednisolone from 4 to 8 mg/die) and in 44 cases only with low doses of glucocorticoids.
All patients provided informed consent before the evaluation.
Out of 154 patients who underwent BAL analysis, 79 fulWlled the selection criteria.
Bronchoalveolar lavage (BAL) was performed as described previously [10] . A concentration of 1 £ 105 cells/ml was made and a cytospin slide preparation was made (Shandon; Runcorn, UK) and stained with MayGrunwald-Giemsa. Two observers blinded to the patients' characteristics counted 400 non-squamous cells. In accordance with others, active alveolitis was deWned as the presence of¸3.0% polymorphonuclear cells (PMNs) and/ or¸2.0% eosinophils on BAL [11, 12] . The Wrst aliquot of BAL Xuid was used for cultural studies.
Pulmonary function tests (PFTs) were performed at baseline and repeated every 12 months. Spirometry was performed according to American Thoracic Society (ATS)/ European Respiratory Society (ERS) recommendations [13] , and DLCO was measured by a single-breath method, and the results expressed as percent of predicted values based on age, sex and height [14] . We considered a value of FVC <80% and DCO <80% of the predicted value abnormal. During the follow-up, we considered worsened patients with a decrease of DLCO >15%, and of FVC >10%.
High-resolution computed tomography (HRCT) scans were scored as reported by Warrick et al. [15] independently by 2 experienced observers, who were blinded with regard to clinical and lung function information. We considered a total score value¸8 abnormal. 99m Technetium-DTPA lung scintigraphy The 99m Tc-DTPA aerosol was produced and administered as described by Coates and Brodovich [16] . The normal range for 99m Tc-DTPA-clearance was deWned as a clearance half-time >40 min.
Statistical analysis
Data were expressed as the mean § standard deviation. Summary statistics were generated using Student's t test or Chi square analysis. Stepwise multiple regression analyses were constructed to determine whether the distribution of BAL count was predictive of outcome or diVerent clinical features of SSc.
Results
Baseline demographics and clinical and serological data for all patients are presented in Table 1 . As expected, there were more women than men (F:M = 8.8:1).
BAL Wndings indicative of "active alveolitis" were evident in 31 patients: a neutrophilic alveolitis was found in 12; eosinophilic alveolitis in 3, mixed alveolitis (neutrophilic + eosinophilic) in 16 patients. The other subjects presented a negative BAL examination. A signiWcant predominance of anti-Topo1 antibodies was found in the alveolitis group (P = 0.017) and of ACA antibodies in patients without alveolitis (P = 0.004). No other diVerences were identiWed between the two groups with respect to age, subset or duration of SSc, and skin score.
PFTs and HRCT scores are reported in Tables 2 and 3 . ACA-positive patients showed signiWcantly lower HRCT scores than patients with anti-Topo1-positive antibodies or without both antibodies and only ANA positivity. Alveolar clearance was signiWcantly accelerated in patients with diVuse SSc and in patients with anti-Topo1 antibodies compared to the patients with ACA antibodies (Tables 2, 3) .
Characteristics of pulmonary involvement are reported in Table 4 . Compared to patients without alveolitis, those with alveolitis had a signiWcant reduction of DLCO (P = 0.000), FVC (P = 0.002), more elevated HRCT scores (total score P = 0.000; severity score P = 0.000; extent score P = 0.000) and more accelerated alveolar clearance (P = 0.020). Moreover, the group with alveolitis showed a signiWcantly higher percentage of patients with honeycombing (P = 0.020) but not with ground glass appearance. Sixty-two patients (26 with pathological and 36 with normal BAL Wndings) were prospectively followed up for 18-36 months and re-evaluated by clinical examination and lung function tests. Seventeen patients were missed or excluded due to incomplete data.
Among 36 patients with normal BAL, 11 (30.5%) showed stable lung function parameters, 13 improved (36.1%) and 12 worsened (33.3%), in this last group 2 patients died of extra-pulmonary complications (the Wrst after 12 months and the second after 18 months from the basal evaluation). In this group, 6 patients with relevant progression of lung Wbrosis were treated with cyclophosfamide (CYC; 750 mg/m2/monthly for 6 months): 3 of them improved and 3 remained stable. The other 6 patients were not treated because they presented reasonable PFT values and clinical conditions.
In the alveolitis group, 12 patients (46.1%) showed stable lung function parameters and 14 worsened (53.8%); 5 of them died (2 for pulmonary Wbrosis and related hypertension, 1 from lung cancer, 2 due to heart failure). Twenty patients (77%) received CYC: 9 (45%) remained stable and 11 (55%) worsened including the 5 patients that died. The remaining 6 patients were not treated for severe co-morbidities; of these patients, 3 remained stable and 3 worsened.
The multiple regression analyses did not show any signiWcant correlation between BAL-positive and BAL-negative patients (data not reported). However, the alveolitis group showed a trend toward a more severe evolution of lung involvement: 33.3% of non-alveolitis patients compared to 53.8% of the alveolitis group had worsened at the end of the follow-up (P = 0.1).
Discussion
Interstitial lung disease (ILD) frequently complicates SSc, leading to loss of quality of life and poor prognosis. Recognition of interstitial Wbrosis in SSc may be delayed due to insidious initial clinical signs and symptoms; moreover, the disease course of Wbrosing alveolitis may vary considerably, making treatment decision diYcult. With the assumption that alveolitis causes progressive Wbrosis, the measurement of inXammatory cells on BAL has become a common clinical practice, useful in identifying patients with ILD who warrant immunosuppression.
Our study revealed a trend toward a more severe course of ILD in the alveolitis group. The absence of signiWcant correlations is probably related to the low number of examined subjects and to a selection bias related to the fact that all the patients already had pulmonary interstitial involvement (see inclusion criteria). Great diVerences in the prevalence of alveolitis have been reported in past studies, varying from 48 to 72%, probably related to the diVerent ratio of patients with diVuse and limited disease and/or to the diVerent autoantibody subsets [11] .
Previous studies underlined the strong correlation between anti-Topo-1 antibodies and pulmonary Wbrosis [8] . Our study conWrmed this correlation, showing a more severe HRCT score and a more accelerated alveolar clearance in patients with anti-Topo-1 antibodies compared to patients with ACA antibodies. The subgroup of patients without ACA and topo-1 antibodies are more similar to the anti-Topo-1-positive patients than ACA-positive patients, suggesting that the presence of ACA antibodies is related to lower lung involvement and probably with a better prognosis (see Table 2 ).
Moreover, the patients with alveolitis showed a more severe lung disease as indicated by a worse lung function, poorer total, extent and severity HRCT scores and more accelerated alveolar clearance. Alveolar clearance is an index of epithelial permeability and has been used as a marker of alveolar inXammation in a number of pulmonary pathologies [17] [18] [19] . In our experience, in non-smoking patients, alveolar clearance may be a further tool in identifying patients with a higher probability of presenting an active alveolitis.
BAL study has been considered to have a prognostic role in predicting increased mortality and the evolution of FVC and DCO over time. These outcomes also depend on whether the patients were treated with CYC [1] or not. Patients with SSc and ILD without alveolitis had a more stable course, while patients with alveolitis showed a signiWcant decline of lung function if not treated.
However, the value of BAL analysis has recently been questioned because it is not yet clear whether a BAL neutrophilia discloses more progressive disease once the severity of disease has been taken into account. Neutrophilia is almost always present when disease is extensive in the lavaged lobe, as judged by HRCT. However, neutrophil levels do not diVer in patients with less extensive lobar involvement and in cases with no HRCT abnormalities [20] . Moreover, patients with BAL neutrophilia tend to have lower DCO levels [21] . Thus, the major inXux of neutrophils may occur when disease is already extensive (and intrinsically more progressive), information that can also be readily obtained from HRCT and pulmonary function evaluation. However, BAL neutrophilia seems to be associated to early mortality but not to late mortality [22] , underlining the fact that BAL may be clinically inappropriate, at least in patients with severe lung disease. Recent data from Scleroderma Lung Study group showed that HRCT has a higher sensitivity than BAL in identifying lung alveolitis. A possible explanation is that interstitial lung disease begins in the lower lobes and at bronchoscopy BAL tends to be performed in the right middle lobe or lingual: for this reason alveolar disease can be missed [23] . In addition, BAL requires experienced personnel to interpret the diVerential cell count. Therefore, caution is warranted in making treatment decisions solely on BAL Wndings. In our analysis, through a follow-up of 12-36 months, we found that alveolitis patients revealed a poor prognosis; most of them worsened or died, even if treated. Moreover, our results are in agreement with data recently reported by two randomized controlled trials [24] showing only a modest beneWcial eVect of CYC on lung function in SSc patients. These unsatisfying results could also be related to the advanced-stage of the disease in our cohort of patients. In fact, a large number of our patients with alveolitis presented signs of irreversible Wbrosis on HRCT.
In conclusion, BAL remains the only tool to exclude lung infections and other causes of lung abnormalities. In our opinion, due to an evident overlap in HRCT scores between patients with or without alveolitis, in the single case the evaluation of only HRCT and/or PFTs may not be suYcient as prognostic tools, and BAL analysis can be considered a useful instrument in evaluating SSc patients with ILD.
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